

REVIEW

Open Access



Epigenetic activities of flavonoids in the prevention and treatment of cancer

Christian Busch¹, Markus Burkard^{1,2}, Christian Leischner², Ulrich M. Lauer², Jan Frank³ and Sascha Venturelli^{2*}

Abstract

Aberrant epigenetic modifications are described in an increasing number of pathological conditions, including neurodegenerative diseases, cardiovascular diseases, diabetes mellitus type 2, obesity and cancer. The general reversibility of epigenetic changes makes them an attractive and promising target e.g. in the treatment of cancer. Thus, a growing number of epigenetically active compounds are currently tested in clinical trials for their therapeutic potential. Interestingly, many phytochemicals present in plant foods, particularly flavonoids, are suggested to be able to alter epigenetic cellular mechanisms. Flavonoids are natural phenol compounds that form a large group of secondary plant metabolites with interesting biological activities. They can be categorized into six major subclasses, which display diverse properties affecting the two best characterized epigenetic mechanisms: modulation of the DNA methylation status and histone acetylation. High dietary flavonoid intake has strongly been suggested to reduce the risk of numerous cancer entities in a large body of epidemiological studies. Established health-promoting effects of diets rich in fruit and vegetables are faced by efforts to use purified flavonoids as supplements or pharmaceuticals, whereupon data on the latter applications remain controversial. The purpose of this review is to give an overview of current research on flavonoids to further elucidate their potential in cancer prevention and therapy, thereby focusing on their distinct epigenetic activities.

Keywords: Epigenetics, HDAC, DNMT, Flavonoids, Phytochemicals, Nutrition, Cancer

Review

Cancer is one of the main causes of death worldwide, and cancer mortality is expected to be more than double in the next 20–40 years [1, 2]. In general, tumour growth is associated with both epigenetic and genetic aberrations resulting in altered gene expression [3]. Furthermore, epigenetic deregulation already occurs during early phases of neoplastic development and was suggested to have a comparable influence on promoting malignant transformation and subsequent tumour growth as genetic mutations [4]. For instance, DNA hypermethylation of promoter regions can cause binding of methyl DNA binding proteins, essential for gene inactivation (mainly of tumour suppressor genes), and global DNA hypomethylation is associated with chromosomal instability [5–7]. Both can be measured in cancer cells, and chromosomal instability is recognized as one of the “hallmarks of cancer” [7, 8]. Additionally, an

altered histone acetylation status can modulate activation or silencing of tumour suppressor genes [9]. Despite the observation that epigenetic changes are heritable in somatic cells and epimutations are rare in non-transformed cells or healthy tissues, it is of interest to note that epigenetic modifications are potentially reversible. Therefore, targeting epigenetic mechanisms is a promising approach for cancer prevention and/or therapy and also for other diseases [5, 10, 11]. According to current estimates, cancer is in, at least, 30–40 % of the cases preventable with appropriate or balanced food and nutrition, regular physical activity and avoidance of obesity [2]. To date, multiple biologically active food components are strongly suggested to have protective potential against cancer formation, even though these effects are not yet firmly established for the majority of these compounds [12]. Examples are methyl-group donors, selenium, fatty acids, and phytochemicals, such as flavonoids, retinoids, isothiocyanates, and allyl compounds [2].

* Correspondence: sascha.venturelli@med.uni-tuebingen.de

²Department of Internal Medicine I, Medical University Hospital, Otfried-Mueller-Str. 27, 72076 Tuebingen, Germany

Full list of author information is available at the end of the article

Epigenetics and cancer

Even though the cells of an organism share the same set of genes, they are differentiated into diverse types of cells and tissues individually characterized by their own biochemical capabilities, (functional) morphology, and gene expression profile. Thus, there is a need for highly ordered regulatory mechanisms determining the fate of each cell. Epigenetic changes are heritable modifications affecting gene expression without causing alterations in the nucleotide sequence itself [13]. The most common epigenetic modifications (Fig. 1) are changes in the DNA methylation pattern, posttranslational histone modifications, and variations in the expression of non-coding microRNA (miRNA). DNA methylation is catalysed by DNA methyltransferases (DNMT), and histone acetylation state is adjusted by opposing activities of histone acetyltransferases (HAT) and histone deacetylases (HDAC). Histone methylation is regulated by histone methyltransferases (HMT) and histone demethylases (HDM) [4]. Of note, aberrant expression or activity of HMT [14, 15] and HDM [16] has also been associated with cancer development [4]. MiRNA is another epigenetic regulatory system that post-transcriptionally influences the regulation of gene

expression and is important for RNA-silencing [17, 18]. Epigenetic changes have been reported during cancer development and are found in genes involved in cell differentiation, proliferation, and survival or apoptosis [4, 19]. CpG dinucleotides (cytosine-phosphate-guanine; cytosine nucleotide followed by a guanine nucleotide) are prone to methylation in the human genome. About 70 % of the CpG are methylated (mostly CpG dinucleotides, which are dispersed throughout the genome), whereas a minority of CpG residues is unmethylated (mostly CpG clusters also known as CpG islands, which are mainly located at the 5' side of genes) [5, 12]. Methylation of CpG islands plays an important role in regulation of gene expression [4, 19]. Approximately 70 % of CpG islands in the human genome are resistant to de novo methylation caused by overexpression of DNMT1 [20], and even though 50 % of all mammalian genes exhibit CpG islands, only a minority is prone to silencing by hypermethylation [5, 20, 21]. Human DNMT (DNMT1, DNMT2, DNMT3a and DNMT3b) specifically methylate the C5 position of cytosine in CpG dinucleotides [5, 22]. DNMT1 maintains DNA methylation patterns, whereas DNMT2 shows only weak methylation activity [23]. DNMT3a and DNMT3b are responsible




Fig. 1 Important epigenetic modifications known to regulate gene expression. **a** DNA methylation of CpG islands in promoter regions by DNA methyltransferases (DNMT) represses gene activity. Posttranslational covalent histone modifications of lysine (K), arginine (R) or serine (S) residues in the "histone tail" also influence gene expression in different ways. **b** Histone acetylation (Ac) catalysed by histone acetyltransferases (HAT) is usually correlated to increased gene activity, whereas histone deacetylation caused by histone deacetylases (HDAC) is considered to decrease gene expression, even though histone hyperacetylation not always matches regions of increased gene activity. **c** Histone methylation (Me) and demethylation by histone methyltransferases (HMT) and histone demethylases (HDM) at lysine or arginine residues show different effects on gene activity depending on number and position of methyl groups. **d** Histone ubiquitylation (Ub) at lysine residues alters histone structure and allows access of enzymes involved in transcription. **e** Histone phosphorylation (P) at distinct serine residues is known to be associated with increased gene expression, and it is also involved in DNA damage response and chromatin remodelling. Phosphorylation at linker histone (LH) H1 is considered to be a signal for the release of histone H1 from chromatin. In general, epigenetic regulation depends on the addition of epigenetic marks by writer enzymes (e.g. DNMT, HMT, HAT) and the removal of these marks by epigenetic eraser enzymes (e.g. HDAC and HDM) as well as epigenetic reader enzymes (not shown in this figure)

for de novo methylation of DNA essential during embryogenesis and other cell differentiation events [20, 23]. Most cancer cells exhibit on the one hand a global DNA hypomethylation and on the other hand, simultaneously, a DNA hypermethylation of specific promoter regions for e.g. tumour suppressor genes or genes important for apoptosis [5, 6]. Malignantly transformed cells modify transcription of genes by changes in the methylation of CpG islands within gene promoter regions and/or by changing posttranslational histone modifications like histone deacetylation as well as distinct histone methylation patterns resulting in decreased gene transcription (Fig. 1). In cancer cells, DNMT1 is both able to maintain DNA methylation and to de novo-methylate DNA of tumour suppressor genes [24]. However, aberrant DNA methylation is not limited to cancer cells; abnormal DNMT expression is also linked to various diseases including depression, anxiety disorder, dementia, autism, cardiovascular diseases, obesity and type 2 diabetes [25–30].

Histone proteins are present in eukaryotic nuclei, where they facilitate the dense packing of DNA and thus play an essential role in the dynamic accessibility of DNA for transcription factors. In humans, there exist two major histone families: the linker histone (LH) and the core histones. Each histone subfamily comprises one or more different variants. The core histones (two each of H2A, H2B, H3, and H4) form an octameric structure called nucleosome, which is a basic element of DNA packaging and consists of 146 base pair units of DNA that are coiled around the octamer of such core histone proteins [12]. The LH H1 binds to the nucleosome and the linker DNA helping to stabilize the chromatin fibre [31, 32]. Histone phosphorylation is mostly associated with actively transcribed genes, but phosphorylation of H1 is also considered to be an important signal for the release of the LH. The dynamic structure of chromatin allows rapid changes in gene regulation [5]. Moreover, the N-termini of histone proteins contain multiple lysine residues and are accessible to covalent modifications such as acetylation, methylation, sumoylation, biotinylation, phosphorylation, glycosylation, and ADP-ribosylation, thus allowing regulation of gene transcription (Fig. 1) [4, 5, 33–36]. Chromatin consists of nucleosome units connected by linker DNA, condensing the volume of the genetic information in eukaryotes [4, 37, 38]. Generally, two distinct states of chromatin are distinguished [4, 38]: heterochromatin is densely compacted and transcriptionally almost inactive; the decondensed euchromatin is only lightly packed, allowing transcriptional activity. Gene expression is hence determined by interactions between DNA methylation, histone modification, and nucleosome positioning influencing chromatin structure. Presence of chromatin remodellers, chromatin-associated proteins, and methyl DNA binding

proteins are also important for structural modification of chromatin [4, 39, 40].

Histone acetylation is one of the most studied post-translational histone modifications to date. Historically, HAT were divided into two groups: type A exhibits a nuclear localization, whereas type B is distributed throughout the cytoplasm and acetylates newly synthesized proteins [5, 33]. To date, three main families of HAT proteins are distinguished among others (MYST, GNAT, and CBP/p300) [4]. Based on their sequence homology to the enzymes found in yeast, HDAC are divided into four classes [41–43]: class I, which comprises the HDAC isoforms HDAC1, HDAC2, HDAC3, and HDAC8, is located predominantly in the nucleus; class IIA, containing HDAC4, HDAC5, HDAC7, and HDAC9 as well as class IIB including HDAC6 and HDAC10 (HDAC6 with two catalytic sites), preferentially shuttle between the nucleus and the cytosol; class III are the nicotinamide adenine dinucleotide (NAD⁺)-dependent sirtuins (SIRT1–7); and class IV consists only of HDAC11, which has catalytic residues in its active centre shared by class I and II [5, 41, 44, 45]. Class I, II, and IV HDAC exhibit homology in both sequence and structure and require a zinc ion for their catalytic activity. These three classes of HDAC completely differ from the sirtuin family regarding sequence and structure. Sirtuins were investigated for their contribution to lifespan prolongation under caloric restriction conditions in lower organisms [4, 46]. In addition, sirtuins exert a variety of different effects on DNA repair mechanisms, chromosomal integrity, cellular senescence, cell cycle progression, and transcriptional activity of tumour-associated proteins such as p53, p73, retinoblastoma protein (pRb), nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B), and the FoxO family [4, 46–48]. Different HDAC isoforms are frequently overexpressed in certain tumour entities, whereas reduced levels of specific HDAC isoforms were observed in some tumour types [4]. Therefore, it is still a big issue that many HDAC inhibitors (HDACi) show only little specificity among the different HDAC isoforms [49] and histone hyperacetylation does not necessarily correlate with regions of increased gene expression [36]. Nonetheless, HDACi seem to be promising cancer-preventive and therapeutic agents capable to reactivate tumour suppressor genes [50, 51]. Genomic instability found in majority of cancer cells causes an increased vulnerability against DNA damaging agents [50]. Therefore, tumour cells might be more susceptible to exogenous compounds causing oxidative stress by production of reactive oxygen species than healthy tissue [52]. Noteworthy, DNA and histone modifying enzymes are highly dependent on essential metabolites such as acetyl-CoA, iron, ketoglutarate, NAD⁺, and S-adenosyl methionine (SAM) and rely on a stable cellular metabolic state [12].

Targeting cancer with epigenetically active compounds *DNA methyltransferase inhibitors in clinical use for the treatment of cancer*

A number of DNMT inhibitors (DNMTi) are already in clinical use or currently under investigation in clinical trials. The pyrimidine nucleoside analogues azacitidine (5-azacytidine, Vidaza[®]) and decitabine (5-aza-2'-deoxycytidine, Dacogen[®]) are approved by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) [4, 53, 54]. How DNMTi specifically affect cancer cells is currently under intensive investigation. The ribonucleoside azacitidine is an analogue of cytosine, which is important for DNA and RNA synthesis [55]. Azacitidine incorporates into RNA and to a lesser extent into DNA [56, 57]. Inclusion into RNA can subsequently cause disassembly of polyribosomes [58, 59], thus disturbing tRNA and ultimately protein synthesis, while incorporation into DNA induces covalent binding to DNMT, thus preventing DNA methylation and very likely replication. Noteworthy, the unspecific disruption of intracellular protein biosynthesis is probably responsible for the high toxicity of azacitidine. In contrast, decitabine is exclusively incorporated into DNA [60], acting as a DNMTi due to covalent binding [57, 61]. Decitabine is supposed to be a more potent DNMTi in vitro than other nucleoside and non-nucleoside inhibitors [62, 63]. Clinical efficacy in the treatment of AML, acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML), and chronic myelomonocytic leukaemia (CMML) is suggested to be caused by DNA demethylating activity of decitabine [64]. Generally, the identification of demethylation events caused by the use of DNMTi in vivo is challenging and shows substantial differences in patients [57, 65]. The majority of studies on humans have investigated the methylation state of the p15 tumour suppressor gene, which is often hypermethylated in MDS and AML. Unfortunately, demethylation and re-expression of p15 could not be correlated to the clinical responses of treated patients [57]. Limitations for the clinical application of the nucleoside inhibitors are their cytotoxicity (especially azacitidine), low drug stability, poor oral availability, and rapid elimination [5, 10]. Although several nucleoside inhibitors have demonstrated anticancer properties in preclinical models and are under clinical investigation, so far, partly due to their toxicity, only azacitidine and decitabine have been approved by the FDA for the treatment of cancer. Distinct flavonoids and other natural compounds like vitamin C (at high doses such as 8 mmol/L, achievable in patients by i.v. administration) [66] are known to act as DNMTi either directly by interaction with the active site of these enzymes or by indirect mechanisms. Therefore, flavonoids and their derivatives may serve as novel and


alternative compounds with DNMTi activity for the prevention and treatment of cancer.

Histone deacetylase inhibitors in clinical use for the treatment of cancer

HDACi can be divided into different chemical classes. HDACi share a metal binding domain enabling them to compete with substrates for the required Zn²⁺-interaction in the binding pocket of the enzymes [5, 33]. Known HDACi are short chain fatty acids (e.g. sodium butyrate and valproate) with in vitro IC₅₀ in the millimolar range, the very potent hydroxamic acids (e.g. trichostatin A (TSA) and vorinostat) displaying IC₅₀ in nano- to micromolar range, benzamides (e.g. MS-275 and N-acetyldinaline), and cyclic tetrapeptides/epoxides (e.g. trapoxin and romidepsin) with IC₅₀ in the nanomolar range [44, 67]. Noteworthy, some HDACi were isolated from natural sources or developed from plant-derived compounds. TSA is an antibiotic isolated from *Streptomyces sp.* with fungicidal properties and one of the most potent HDACi known to date with an IC₅₀ in the low nanomolar range. Its production is expensive and TSA displays several undesirable side effects [5, 67]. Vorinostat and romidepsin progressed to clinical trials and are the first HDACi approved by the FDA for the treatment of cutaneous T cell lymphoma. Vorinostat is a chemical compound suitable for docking into the active site of HDAC of classes I, II and IV [5, 68]. Romidepsin is a natural product obtained from *Chromobacterium violaceum* and can be considered as a prodrug [51]. More recently, the HDACi belinostat and panobinostat were FDA approved. Belinostat is used in the treatment of relapsed or refractory peripheral T cell lymphoma, and panobinostat is available for the treatment of recurrent multiple myeloma in combination with bortezomib and dexamethasone [69, 70]. Despite the promising potential of HDACi in the treatment of some cancer entities, there have also been issues concerning low specificity to the different HDAC isoforms and adverse effects [36]. In this regard, some promising inhibitors like TSA were not approved for the clinical use and an intensive search for novel epigenetic drugs combined with the evaluation in clinical trial is ongoing [71]. Interestingly, some innocuous phytochemicals including flavonoids display a HDACi activity.

Flavonoids

Flavonoids are a large group of secondary plant metabolites (also known as phytochemicals). More than 4000 different flavonoids are described so far [72]. Flavonoids belong to the polyphenol family. The basic chemical structure of flavonoids is the flavan backbone. It comprises two phenolic rings (named A and B) linked by an oxygen-containing heterocycle (C) and is the structural feature shared by all flavonoids (Fig. 2). Depending on



their chemical structure, flavonoids are divided into six subclasses: flavan-3-ols (also known as flavanols or catechins), flavonols, flavones, flavanones, isoflavones, and anthocyanidins [48]. Variations in the saturation, hydroxylation and glycosylation of the rings are responsible for the large number of individual compounds within each of these subclasses. Flavonoids are widely distributed throughout the plant kingdom, where they function as pigments, phytohormones, and protect against UV radiation, insect pests, and plant diseases [73, 74]. Furthermore, flavonoids have been reported to exert a number of biological activities in mammals, such as antibacterial, antiviral, analgesic, antiallergic, hepatoprotective, cytostatic, apoptotic, oestrogenic and anti-oestrogenic functions, to name only a few [75–77]. These diverse biological activities have been attributed to many molecular mechanisms, including the modulation of the activities of phase I and II detoxification enzymes, direct and indirect antioxidant activities [76, 78, 79], inhibition of protein kinases, effects on cell cycle, modulation of gene transcription, and epigenetic activities [5, 80]. The described effects are important due to the presence of these compounds in the human diet and their regular ingestion. According to a French study, published by Brat and colleagues, the total polyphenol intake from fruit is about three times higher compared to that from


vegetables, based on the overall low polyphenol level in vegetables [81]. The mean total daily polyphenol intake of French adults is estimated to be 1193 ± 510 mg/day [82]. The flavonoid intake of the Australian population e.g. is estimated to be 454 mg/day with 92 % flavan-3-ols [83]. The estimated mean daily total flavonoid intake in US adults e.g. is described by Chun and coworkers with 189.7 mg/day, with a portion of 83.5 % from flavan-3-ols, 7.6 % flavanones, 6.8 % flavonols, 1.6 % anthocyanidins, 0.8 % flavones, and 0.6 % isoflavones [84].

Epigenetic activities of flavonoids


Flavan-3-ols

Rich sources of flavan-3-ols are e.g. apples, grapes, wine, cacao, and tea [72] (Fig. 2). Tea is the most widely consumed beverage worldwide next to water [85, 86]. Green, black, and oolong tea, which differ by their degree of fermentation, are the most popular teas. Green tea leaves are only dried and roasted, oolong tea is partially fermented, and black tea extensively fermented [87–90]. All of these teas contain varying amounts of e.g. (+)-catechin, (–)-epicatechin (EC), (–)-epicatechin-3-gallate (ECG), (–)-epigallocatechin (EGC), and (–)-epigallocatechin-3-gallate (EGCG). The flavan-3-ol EGCG is the most abundant flavonoid in green tea [5, 90, 91] (Fig. 3). EGCG induces apoptosis (e.g. in HaCaT, L5178Y, and


Flavan-3-ols: Catechin




Epigallocatechin gallate




Flavonols: Kaempferol




Quercetin




Myricetin




Fisetin




Flavones: Apigenin




Luteolin




Flavanones: Hesperetin




Naringenin



Isoflavones: Genistein



Daidzein



Flavonolignan: Silibinin




Fig. 3 Chemical structures of flavonoids known to exert epigenetic activity. Flavan-3-ols: (+)-catechin and epigallocatechin-3-gallate; flavonols: kaempferol, quercetin, myricetin, and fisetin; flavones: apigenin and luteolin; flavanones: hesperetin and naringenin; isoflavones: genistein and daidzein; flavonolignan: silibinin

DU 145 carcinoma cells, but not normal human keratinocytes) [92] and cell cycle arrest in A-431 human epidermoid carcinoma cells [92] while reducing oxidative stress (e.g. metal ion chelation by vicinal dihydroxyl and trihydroxyl structures) and angiogenesis [87, 93]. EGCG was further shown to inhibit DNMT activity by direct enzyme interaction leading to decreased cellular concentrations of 5-methylcytosine; contrariwise, Stresemann and coworkers reported no effect of EGCG on DNMT activity (2–50 $\mu\text{mol/L}$) in cancer cells after a 3-day treatment [5, 94]. It was described that Mg^{2+} enhances the inhibitory effect of EGCG on human DNMT activity [5, 95]. In the context of human cell lines, EGCG (20 $\mu\text{mol/L}$) inhibits DNMT activity in oesophageal (KYSE-150), colon (HT-29), prostate (PC-3), and breast (MCF7 and MDA-MB-231) cancer cells [2], and also other tumour entities [96–98]. An indirect inhibition of DNMT by flavan-3-ols is mediated by an increase in *S*-adenosyl-*L*-homocysteine (SAH). This increase in SAH may be caused by catechol-*O*-methyltransferase (COMT) mediated methylation of these flavonoids. Tea catechin-mediated COMT inhibition was investigated in the context of rat, mouse, and human liver cytosol [99, 100]. SAH itself, which is formed out of the methyl donor SAM, is a potent inhibitor of DNMT [5, 101]. EGCG was found to contribute to the degradation of DNMT3a and HDAC3 in human HCT 116 colon cancer cells [102]. Interestingly, EGCG treatment of MCF7 and MDA-MB-231 breast cancer cells resulted in downregulation of human telomerase reverse transcriptase (hTERT) expression and thus decreased telomerase levels. As the telomerase is responsible for lengthening of telomeres in DNA strands, this enzyme is almost absent in normal cells, whereas it is considerably expressed in spontaneously immortalized cells such as cancer cells. Even though tea catechins are less potent DNMTi than the chemical nucleoside inhibitors, counted as non-nucleoside inhibitors, they could exert a stable and moderate DNMT inhibition due to long-term consumption of green tea. Catechins are also hypothesized to be more gene and tissue specific than the nucleoside inhibitors, although experimental evidence is lacking [5, 63]. Sustained consumption of tea may be a promising cancer-preventive or even cancer-therapeutic approach [5]. In addition, EGCG modulates cellular HAT activity and thus histone acetylation and thereby alters the chromatin structure [50, 103]. EGCG (100 $\mu\text{mol/L}$) was found to inhibit the majority of HAT enzymes confirmed by colourimetric HAT activity assay and in vitro fluorography analyses of HAT enzymes [5, 103]. Moreover, EGCG also modulates miRNA expression in hepatocellular carcinoma cells [87], which further contributes to its broad spectrum of epigenetic activities. Noteworthy, flavan-3-ols exert further molecular effects, which could contribute to their inherent anticancer activity, such as inhibition of dihydrofolate reductase leading to reduced cellular levels

of folic acid [104]. Several in vivo studies investigated the epigenetic modulation mediated by flavan-3-ols, especially ECGC, and their impact on cancer formation and tumour growth. Henning and coworkers showed that substitution of drinking water with brewed green tea (about 700 mg/L total green tea catechins) using male severe combined immunodeficiency (SCID) mice with human LAPC4 prostate cancer xenografts [105] resulted in a reduced tumour volume. The results of the prostate cancer model indicate that green tea inhibited mRNA and protein expression of DNMT1 in the tumour cells, which in turn reactivated antioxidative enzymes [105].

Another interesting study that focuses on colorectal carcinogenesis in the azoxymethane-Apc^{Min/+} mouse model investigated green tea as well. In comparison to the water control group, administration of green tea solution (0.6 % w/v), as only source of beverage, reduced the number of newly formed tumours significantly. Moreover, this study detected a green tea-mediated rise in protein and transcript levels of retinoid X receptor alpha (RXRa), which was found to be selectively downregulated in intestinal tumours of control mice. Analyses of CpG sites at the promoter region of the RXRa gene illustrated that consumption of green tea decreased CpG methylation [106]. Therefore, the authors suggested that in this in vivo intestinal cancer model, the demethylating activity of the green tea solution decelerates or even prevents tumourigenesis.

Instead of oral administration, the effects of flavonoids on tumour formation by topical application were also investigated by in vivo studies. EGCG in a hydrophilic cream as vehicle was tested for its antiphotocarcinogenic activity using a SKH-1 hairless mouse model [107]. Measuring tumour incidence and tumour size, the topical application of ECGC displayed a pronounced protection against photocarcinogenesis [107]. Moreover, the transformation of papillomas to carcinomas by ultraviolet B (UVB) seemed to be inhibited by EGCG as well [107].

Despite these promising and interesting findings for green tea, some studies demonstrated that the demethylating activity is not always detectable in an in vivo situation. For instance, the oral consumption of green tea polyphenols (0.3 % in water) by transgenic adenocarcinoma of the mouse prostate (TRAMP) mice with an age of 4 weeks did not affect the DNA methylation of prostate, gut or liver. Moreover, the administration of green tea polyphenols did not inhibit tumour progression in this murine prostate model [108, 109].

Flavonols

Flavonols are abundant in vegetables and fruits, among which onions represent a rich dietary source (Fig. 2). Other important dietary sources for flavonols include tea, apples, berries, and wine. Quercetin is the predominant

flavonol [110] (Fig. 3). Bioavailability of quercetin was extensively investigated compared to most of the other flavonoids [111]. It seems that the glycosylation state of quercetin strongly influences its intestinal absorption rate [72]. While both, the glycosides and aglycone of quercetin are absorbed, the bioavailability of the glycosides is much better [72]. Due to its long elimination half-life in vivo [72], daily intake (e.g. 1 week ingestion of a diet rich in onion) resulted in an accumulation and an increase of quercetin from $0.04 \pm 0.04 \mu\text{mol/L}$ before to $0.63 \pm 0.72 \mu\text{mol/L}$ [112–114]. Fisetin is found in strawberries, apples, onions, wine, and tea [46, 115], whereas grapes, berries, red wine, and tea are sources of myricetin [116, 117] (Fig. 3). Kaempferol is found in fruits and vegetables such as tomatoes, hop, red grapes, grapefruit, strawberries, and *Ginkgo biloba* [118] (Fig. 3). The flavonols quercetin, fisetin, and myricetin were tested for DNMT inhibition and their IC_{50} values were determined: quercetin ($1.6 \mu\text{mol/L}$), fisetin ($3.5 \mu\text{mol/L}$), and myricetin ($1.2 \mu\text{mol/L}$) [2, 95]. All three flavonols inhibited DNMT1-mediated DNA methylation in a concentration-dependent manner [95]. Myricetin, the flavonol exerting the strongest DNMT inhibition, has a pyrogallol moiety (structurally related to benzene with three vicinal hydroxy groups) similar to the gallic acid moiety of EGCG [5, 95]. It has also been shown that the two flavonols quercetin and fisetin activate sirtuins [5, 80], whereas quercetin ($100 \mu\text{mol/L}$) seems to drive both HAT activation and HDAC inhibition determined with a colorimetric activity assay, which does not distinguish between HAT or HDAC isoforms [119]. Consistent with these findings, increased histone H3 acetylation was described after quercetin exposure of leukaemia HL60 cells [50]. Noteworthy, investigation of the chemopreventive and therapeutic capabilities of quercetin in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch (HBP) carcinoma model showed positive correlation between inhibition of HDAC1 and DNMT1 and anticancer effects exerted by quercetin, such as induction of cell cycle arrest and apoptosis as well as inhibition of angiogenesis and invasion. If quercetin was administered at the same time with DMBA, both the tumour incidence and the tumour burden were decreased. Treatment with quercetin after DMBA exposure significantly slowed tumour growth [120]. The flavonol kaempferol exhibits also a distinct inhibitory activity towards HDAC enzymes. In particular, our group observed a hyperacetylation of histone H3 by kaempferol (visualized by Western blot of hyperacetylated H3 after a 24-h treatment of human hepatoma cell lines HepG2 and Hep3B as well as the colon cancer cell line HCT 116). This effect seemed to depend on inhibition of class I, II, and IV HDAC enzymes (HDAC1-11) [118]. In addition, reduced cellular viability and proliferation was demonstrated for HepG2, Hep3B, and HCT 116 cancer cells after incubation with kaempferol concentrations that mediated HDACi activity [118].

Flavones

Celery, chamomile, and parsley are rich sources of apigenin [103] (Figs. 2 and 3). Carrots, peppers, celery, olive oil, peppermint, thyme, rosemary, and oregano are important dietary sources of luteolin [121] (Fig. 3). Apigenin and luteolin exert inhibitory effects on 5-cytosine DNMT as shown, using nuclear extracts of KYSE-510 cells [122]. Both flavones were tested at concentrations of 20 and $50 \mu\text{mol/L}$. Luteolin showed a more pronounced inhibition of DNMT enzymes with an efficacy of about 50 % at $50 \mu\text{mol/L}$, while apigenin only displayed a 35 % inhibition at $50 \mu\text{mol/L}$ [122]. Apigenin causes cell cycle arrest and apoptosis in human prostate cancer cells (PC-3 and 22Rv1) [123]. The latter study revealed that apigenin-mediated growth inhibition is due to inhibition of class I HDAC. The authors showed that treatment of PC-3 and 22Rv1 cells with 20–40 $\mu\text{mol/L}$ apigenin inhibited HDAC1 and HDAC3 on mRNA and protein levels resulting in a global histone H3 and H4 hyperacetylation. Further experiments in a PC-3 xenograft model of athymic nude mice showed that oral intake of apigenin at a constant daily dose of 20 or 50 mg per mouse for 8 weeks inhibited HDAC activity and expression of HDAC1 and HDAC3 in the cancer tissue and resulted in reduced tumour growth [123].

Flavanones

Two flavanones tested for epigenetic activity are hesperetin and naringenin (Figs. 2 and 3). Flavanones are abundant in the peel of citrus fruits, which are not directly ingested in significant amounts, and thus the major dietary sources for flavanones are citrus juices [124, 125]. Both hesperetin and naringenin inhibit DNMT activity in nuclear extracts of human oesophageal squamous cell carcinoma KYSE-510 cells incubated for 1.5 h with 20 or $50 \mu\text{mol/L}$. DNMTi activity was not specified for particular isoforms, and hesperetin was found to be the more potent inhibitor of both tested flavanones [122].

Isoflavones

Isoflavones are found e.g. in soybeans, fava beans, and kudzu [87] (Fig. 2). Genistein and daidzein, the most prominent and well-characterized isoflavones are structurally similar to 17β -oestradiol, which allows their binding to oestrogen receptors and explains their, albeit weak, phyto-oestrogenic activity [126–128] (Fig. 3). Regarding the epigenetic activity of isoflavones, it was demonstrated that genistein, daidzein, and biochanin A inhibit DNMT enzymes [5, 122, 129]. Genistein (at concentrations of 2–20 $\mu\text{mol/L}$) reduced genomic DNA hypermethylation and subsequently increased the protein level of retinoic acid receptor β (RAR β), p16^{INK4a}, and O⁶-methylguanine DNA methyltransferase (MGMT) in human KYSE-510 cells [129]. Further studies confirmed that genistein inhibits

DNMT1, DNMT3a and DNMT3b, and leads to activation of silenced tumour suppressor genes [130]. A similar dose-dependent competitive and non-competitive inhibition of DNMT by reduction of the cellular availability of SAM was found with 20–50 $\mu\text{mol/L}$ genistein in oesophageal squamous cell carcinoma KYSE-150 cells and the prostate cancer cells lines LNCaP and PC-3 [129]. Interestingly, genistein represses hTERT expression in breast cancer cells, paradoxically by promoter demethylation, which is similar to the activity of ECGC described above [131–133]. The epigenetic activity of genistein was also assessed in vivo. Maternal genistein diet of agouti mice during pregnancy was found to have long-term effects on offspring and altered coat colour due to epigenetic modulation. In this context it is interesting that prenatal exposure to genistein (270 mg/kg feed) not only leads to lifelong changes in the DNA methylation patterns but also has an impact on gene expression including in the haematopoietic lineage [134]. The epigenetic activity of dietary genistein in timed pregnant Sprague-Dawley rats and their male pups was also investigated. Genistein was fed either as a soy protein lysate or purified compound (equivalent to 140 mg/kg genistein aglycone) and compared to a genistein-free control diet. Male pups were injected with the chemical carcinogen azoxymethane, which decreases levels of acetylated histone H3. Colon samples were investigated 6 weeks after carcinogen injection. In this experimental setting, dietary genistein modulated the responses of wingless-related integration site (Wnt) genes by DNA methylation and histone modifications during carcinogen exposure. Thus, it was suggested that dietary genistein may prevent neoplastic development [135]. This emphasizes that genistein has multiple effects not only on DNMT enzymes but also on posttranslational histone modifications like histone demethylation, HAT activation, and SIRT inhibition [50, 135, 136]. Treatment of MCF7 and MDA-MB-231 breast cancer cells with genistein (18.5 $\mu\text{mol/L}$) and daidzein (78.5 $\mu\text{mol/L}$) decreased histone trimethylation and increased histone acetylation of six different genes each responsible for a protein associated with breast cancer (histone-lysine *N*-methyltransferase (EZH2), breast cancer 1, early onset (BRCA1), oestrogen receptor α (ER α), oestrogen receptor β (ER β), nuclear receptor coactivator 3 (SRC-3), and P300) [137]. Genistein inhibited HDAC activity by 15 % at concentrations of 5–20 $\mu\text{mol/L}$ in KYSE-510 cells. Although genistein is a less potent inhibitor of DNMT than ECGC, it is more stable in solution and the additional weak HDAC inhibitory activity of genistein was suggested to result in comparable gene reactivation as observed for ECGC [5, 122]. Thus, genistein-mediated gene reactivation may be based on a synergistic effect of DNMT and HDAC inhibition [5, 138]. Moreover, there is a strong body of evidence that genistein and other isoflavones regulate miRNA expression in cancer cells and hence have an impact on

tumour growth [87, 133, 139]. Despite the promising preventive and therapeutic potential of genistein, there is also a debate on possible deleterious effects by genistein administration in the treatment of breast cancer and probably other hormone dependent cancer entities in humans [140]. Another report also described disadvantageous effects of isoflavones in regard to increased formation of metastases [141].

Anthocyanidins

Anthocyanidins are responsible for the blue and red colours of plants and are found e.g. in many berries, cherries, and grapes [72] (Fig. 2). Anthocyanidins are flavonoid aglycones; their glycosides are called anthocyanins. Well-known anthocyanidins include cyanidin, delphinidin, malvidin, and pelargonidin, to name only a few. To the best of our knowledge, the epigenetic activities of the anthocyanidins have not yet been investigated.

Flavonolignans

From a chemical point of view, flavonolignans are composed of a flavonoid fused to a lignan (Fig. 2). Silibinin is the most active flavonolignan and is found e.g. in a standardized extract from milk thistle known as silymarin, which is an antidote used to prevent toxic liver damage upon ingestion of toxins (e.g. mycrocristin-induced toxicity in mice, cases of mushroom poisoning in humans) [142–144] (Fig. 3). Silibinin contains two diastereomers named silybin A and B [145]. In a model of colon cancer progression with primary human colon adenocarcinoma cells SW480 and the corresponding metastatic derivative SW620, silibinin inhibited DNMT activity in both cell lines [146]. However, no effect on HDAC activity was observed, which contrasted with previous reports showing inhibitory effects of silibinin on HDAC enzymes [147–149]. Lah and coworkers used high concentrations of silibinin (120 $\mu\text{mol/L}$ and 240 $\mu\text{mol/L}$, respectively) for 24 h to treat Huh7 human hepatoma cells and found significantly increased levels of acetylated histones H3 and H4 [147]. The effect of silibinin on human hepatocellular carcinoma xenografts in nude mice was assessed by Cui and colleagues. After subcutaneous inoculation of Huh7 cells, mice were treated with vehicle, 80 mg/kg or 160 mg/kg silibinin per day, respectively. A 5-week treatment with silibinin resulted in elevated levels of acetylated histones H3 and H4 in the tumour tissue and in reduced tumour growth [148]. Similar effects were reported for the non-small cell lung cancer cells H1299 and a corresponding xenograft mouse model (athymic (nu/nu) male nude mice were subcutaneously injected with H1299 cells and treated with 100 mg/kg silibinin per day for 4 weeks) [149]. The authors found inhibition of HDAC1, HDAC2, and HDAC3 resulting in increased levels of acetylated histones H3 and H4. Promising synergistic effects of silibinin with the well-known

HDACi compounds TSA and vorinostat were also reported [149].

Conclusions

Epigenetic activities of flavonoids and their impact on human health

A multitude of biological effects has been reported for flavonoids, including their influence on phase I and II detoxifying enzyme activity, antioxidant properties, protein kinase inhibition, cell cycle regulation, transcriptional, and epigenetic activities. Flavonoids have attracted increasing attention due to their diverse health-promoting effects. Especially the possible chemopreventive and antitumour activities of flavonoids and other natural compounds are noteworthy due the fact that cancer incidence and mortality is globally still exceptionally high [150]. Interestingly, the cancer incidence varies between the different regions of the world, and for decades observational studies have been suggesting that nutritive and lifestyle risk factors strongly contribute to this discrepancy (Fig. 4) [151–153]. According to this, it was currently estimated that many cancer-related deaths could be prevented by adequate lifestyle modifications, particularly changes in diet or nutrition [12]. The consumption of diets rich in fruits and vegetables has been consistently associated with a significantly reduced risk of cancer development with an impact on both cancer initiation and progression [87, 154–158]. Importantly, emerging evidence strongly suggests that diet

is a major modulator of the epigenetic state of cells and is able to reverse abnormal or altered gene expression patterns [87]. This is in line with growing evidence for sustained remodelling of the human epigenome during lifetime by nutrition, exercise, mental pressure or stress and environment (Fig. 4) [159]. The importance of such acquired epigenetic patterns is supported by observations in monozygotic twins, where one is affected by several diseases such as diabetes mellitus, while the other remains unaffected [160]. Young monozygotic twin siblings seem to be epigenetically relatively similar to each other, whereas epigenetic changes and a different gene expression profile were found in aged twin pairs [160]. These differences are indicated to depend on environmental factors such as lifestyle and time spent together [160]. Greatest changes in DNA methylation patterns were observed in aged monozygotic twins if they did not share environments during lifetime [12]. According to epidemiological studies and dietary interventions in animal models, it was strongly suggested that nutrition-derived epigenetic modifiers influence the epigenome and even the cancer risk programming of unborn children in utero [2, 12]. There is also increasing evidence that maternal malnutrition and deranged metabolism could have detrimental effects on offspring (“fetal programming”) and it is very likely that epigenomes are continuously shaped during lifetime exerting effects also on subsequent generations [12]. Therefore, dietary factors, including certain flavonoids, may have




Fig. 4 Modulation and interaction of epigenetic mechanisms. Gene regulation depends on a complex interplay between posttranslational histone modifications and DNA methylation. MiRNA either directly affect gene expression or modulate other epigenetic mechanisms. Epigenetic activity in general is influenced by several exogenous and endogenous factors including nutrition

beneficial effects on human health by remodelling of the epigenome and other modes of action. Representatives of the flavonoid subclasses flavan-3-ols (catechin and EGCG), flavonols (kaempferol, quercetin, myricetin, and fisetin), flavones (apigenin and luteolin), flavanones (hesperetin and naringenin), isoflavones (genistein and daidzein), and the flavonoid-related class of flavonolignans (silibinin) have been reviewed above focusing on DNA methylation and histone acetylation [2, 5, 95, 122, 146]. As flavonoids are present in fruits, vegetables, and tea, a short overview of food containing high amounts of these epigenetically

active flavonoids is depicted in Table 1. Nonetheless, it remains controversial if e.g. long-term exposure to “epigenetic diets” rich in flavonoids or flavonoid supplements could also induce unwanted effects due to their lack of specificity regarding distinct isoforms of enzymes responsible for epigenetic modulation like HAT and HDAC [12]. Low specificity was found to limit the clinical application of epigenetic drugs like HDACi, and despite their epigenetic activity, flavonoids target a multiplicity of other pharmacological pathways. On the one hand, these pleiotropic effects such as inhibition of angiogenesis, inflammatory

Table 1 Food containing high amounts of epigenetically active flavonoids

Description	Class	Flavonoid	Ø mg/100 g	Sources of data
Grapefruit, raw (not specified as to colour) (<i>Citrus paradisi</i>)	Flavanones	Hesperetin	1.50	^a USDA Database for the Flavonoid Content of Selected Foods: e.g. [193]
		Naringenin	53.00	
	Flavonols	Kaempferol	0.40	
		Quercetin	0.50	
Onions, red, raw	Flavones	Apigenin	0.24	^a USDA Database for the Flavonoid Content of Selected Foods: e.g. [193–196]
		Luteolin	0.16	
	Flavonols	Kaempferol	0.70	
		Myricetin	2.16	
Soybeans, mature seeds, raw (all sources)	Isoflavones	Quercetin	39.21	^b USDA Database for the Isoflavone Content of Selected Foods: e.g. [197–202]
		Daidzein	62.07	
		Genistein	80.99	
Spices, parsley, dried (<i>Petroselinum crispum</i>)	Flavones	Apigenin	4503.50	^a USDA Database for the Flavonoid Content of Selected Foods: e.g. [196]
		Luteolin	19.75	
Strawberries (including frozen unsweetened strawberries)	Flavonols	Fisetin	16	[203]
		Kaempferol	0.49	
		Myricetin	0.35	
		Quercetin	0.46	
Cacao beans	Flavan-3-ols	(+)-Catechin	88.45	^a USDA Database for the ^a Flavonoid Content of Selected Foods: e.g. [206]
		(-)-Epicatechin	99.18	
Tea, black, brewed, prepared with tap water	Flavan-3-ols	(+)-Catechin	1.51	^a USDA Database for the Flavonoid Content of Selected Foods: e.g. [196, 207–209]
		(-)-Epigallocatechin 3-gallate	9.36	
		Quercetin	2.19	
	Flavonols	Kaempferol	1.41	
		Myricetin	0.45	
Tea, green, brewed, decaffeinated	Flavan-3-ols	(-)-Epigallocatechin 3-gallate	26.05	^a USDA Database for the Flavonoid Content of Selected Foods:
		Quercetin	2.77	
	Flavonols	Kaempferol	1.00	
		Myricetin	1.00	

Flavonoid and isoflavone content are summarized in the USDA databases cited below:

^aBhagwat, S., Haytowitz, D.B. Holden, J.M. (Ret.). 2013. USDA Database for the Flavonoid Content of Selected Foods, Release 3.1. U.S. Department of Agriculture, Agricultural Research Service. Nutrient Data Laboratory Home Page: <http://www.ars.usda.gov/News/docs.htm?docid=6231>

^bBhagwat, S., Haytowitz, D.B. Holden, J.M. 2008. USDA Database for the Isoflavone Content of Selected Foods, Release 2.0. U.S. Department of Agriculture, Agricultural Research Service, Nutrient Data Laboratory Home Page: <http://www.ars.usda.gov/News/docs.htm?docid=6382>

processes, and induction of apoptosis [161, 162] can be beneficial for the treatment of several diseases and in particular cancer where most of mono-therapeutic efforts are non-satisfying [163, 164]. On the other hand, there is also a risk to induce unwanted side effects, and there is little knowledge about their bioavailability (e.g. aglycones and glycosides), metabolism, and in particular about their bioactivity and the fate of arising metabolites. Moreover, many clinicians are generally incredulous towards phytochemicals in the treatment of life-threatening diseases, and appropriate animal studies and clinical studies with flavonoids are still very limited. In terms of cancer treatment, oncologists are sceptical towards the antioxidant effects exerted by flavonoids, especially when combined with classical cytostatic drugs. It is still not clear if antioxidant properties are a problematic issue during chemotherapy. Generally, the use of flavonoids especially at super-physiological doses as conducted in several in vitro studies has to be carefully evaluated for the in vivo situation. Moreover, most flavonoids and other polyphenols with epigenetic activity in vitro have not yet been tested in animal models, and when tested, only a few epigenetic marks have been analysed in depth. In addition, the overall functional relevance of epigenetic modulation exerted by flavonoids and other natural compounds in chemoprevention and chemotherapy has to be further elucidated [165].

According to these uncertainties and hindrances, the discussion on epigenetic modulation by flavonoids and their impact on human health remains highly controversial and gives a possible explanation for the missing breakthrough of these natural compounds in clinical use [166–171].

Intake of flavonoids and cancer risk

According to the currently available data, the intake of a balanced diet is strongly recommended for maintaining health and for the prevention of a broad spectrum of “Western civilization” diseases like cancer. Current studies reveal that malnutrition and obesity are under-recognized, but are important risk factors for cancer, cancer recurrence, and cancer-related mortality. Moreover, obesity negatively affects treatment outcome as well as prognosis of cancer patients [172]. Due to the significantly increased prevalence of obesity on a global scale, nutrition and lifestyle have become important aspects of cancer prevention and therapy. Therefore, many phytochemicals and/or their respective metabolites derived from fruits, vegetables or nutrients are currently analysed for their potential beneficial effects on health. In this respect especially, flavonoids as a large group of secondary plant metabolites have been under extensive investigation for decades [72]. Importantly, it has been controversially discussed if flavonoids exert any protection against cancer in humans. Epidemiological studies found conflicting results with respect to the effects of

flavonoid intake and cancer incidence and mortality. For pancreatic cancer, a large prospective study with an analytic cohort of 537,104 persons found no evidence that flavonoids have a protective role in carcinogenesis (hazard ratio (HR) = 1.09) [173]. Another large prospective study with a cohort of 477,312 men and woman recruited in 10 European countries also found no association between total flavonoid intake and bladder cancer risk [174]. In contrast, some experimental data suggest that specific flavonoids could even promote tumour formation in certain subsets of patients. A randomized placebo-controlled study on female patients illustrated that the supplementation of soy, which contains high amounts of isoflavones, may upregulate genes that drive cell cycle and proliferation pathways and therefore could adversely affect breast carcinogenesis [175]. In this regard, a large prospective cohort study with a multi-ethnic population of 84,450 women examined the potential connection of dietary isoflavone intake and overall breast cancer risk. Interestingly, no statistically significant association between dietary isoflavone intake and overall breast cancer risk was found (HR = 0.96) [176]. In the same study, some ethnic groups benefited from a high isoflavone intake and had a reduced risk in breast cancer incidence, which is in line with a meta-analysis of corresponding prospective studies (relative risk (RR) = 0.89 on average with RR = 0.76 for Asian women and only RR = 0.97 for Western women) [177]. Although the impact of specific flavonoids on particular tumour entities is discussed controversially in the literature, the overall evidence suggests that flavonoids rather protect from cancer.

Referring to this, the cancer-preventive potential of dietary flavonoids was recently reviewed by Romagnolo and Selmin [178]. Epidemiological studies suggest that flavonoid ingestion reduces the risk of versatile cancer entities like pancreas, prostate, lung, colon, breast, and prostate cancer even though results are sometimes inconclusive [178]. It is challenging to construe data obtained from epidemiological studies because the majority are case-control or retrospective studies and less prospective trials, respectively [178].

In this regard, a prospective study involving 9959 men and women observed a reduction in lung cancer cases associated with increased flavonoid intake over a period of 24 years (RR = 0.54) [179].

Focusing on the subclasses of flavonoids, in an Italian case-control study with about 10,000 cancer patients and 16,000 controls, the risk to develop oral or laryngeal cancer was inversely related to the intake of total flavonoids (odds ratio (OR) = 0.56 and 0.60, respectively), flavanones (OR = 0.51 and 0.60, respectively), and flavonols (OR = 0.62 and 0.32, respectively) [178, 180]. Comparable results for laryngeal cancer were reported for flavanones (OR = 0.60), flavan-3-ols (OR = 0.64), and flavonols (OR = 0.32) [181], whereas no association was found for isoflavones,

anthocyanidins, and flavones [178]. Flavanone intake mainly by consumption of citrus fruits reduced oesophageal cancer risk (OR = 0.38) [178, 182]. Protective effects against gastric cancer were reported for quercetin and EGCG [183, 184], whereas an increased risk for higher isoflavone intake was described in Japanese women simultaneously using exogenous hormones [185]. Total flavonol and particularly kaempferol intake was reported to reduce the risk of pancreatic cancer (OR = 0.78) [186].

In line, the large prospective study of Zamora-Ros and colleagues suggested a protective association between dietary intake of flavonols and the risk of bladder cancer (HR = 0.74) [174]. Two large studies analysing the risk of epithelial ovarian cancer concluded that several flavonoids and in particular flavonols seem to be associated with a reduced risk of ovarian cancer (HR = 0.85 for total flavonoids and RR = 0.75 for the combined intake of myricetin, kaempferol, quercetin, luteolin, and apigenin) [187, 188]. For isoflavones (another subclass of flavonoids), a randomized placebo-controlled trial displayed that uptake of isoflavones could reduce the prostate cancer risk [189]. These results are in line with the observation that supplementation of isoflavonoids seems to diminish the increase of serum prostate-specific antigen (PSA) in men following local therapy [190]. Even though there are obvious study limitations based on diet and lifestyle variables, several trials detected an association between dietary intake of specific flavonoids or flavonoid subclasses and reduced occurrence of certain cancer types. The molecular mechanisms underlying the anti-cancer properties of flavonoids are numerous and include the modulation of cellular signalling pathways, direct and indirect antioxidant activities, and epigenetic phenomena. The latter are important for tumour formation and growth and thus also for cancer prevention and therapy. Flavonoids are epigenetically active both *in vitro* and *in vivo*, albeit very high and often non-physiological concentrations have been used in experiments to investigate their epigenetic activities. Nevertheless, some flavonoids, such as quercetin, accumulate in blood and tissues over time [72, 112] and may thus reach sufficiently high concentrations to exert epigenetic activity. Furthermore, flavonoids may act synergistically with each other, with other natural compounds present in the diet and/or with synthetic drugs, and may thereby facilitate changes to the epigenome at low concentrations [191]. Nonetheless, low bioavailability of flavonoids is a crucial issue (due to restricted intestinal digestive and absorptive dynamics, metabolism by the intestinal microflora and after absorption) [5, 192]. Further in-depth research and prospective as well as mechanistic studies are required to investigate the beneficial effects of the different flavonoids in detail. Based on these data, simple changes in diet and food intake could contribute to prevention and

treatment of human diseases including cancer. Safe, effective, and especially pleiotropic chemopreventive compounds are urgently needed considering the fact that cancers often exhibit long latencies of about 20 years and that detrimental changes in malignant cells should be counteracted as early as possible [12]. Many flavonoids and other polyphenols seem to regulate multiple targets e.g. involved in cancer-inflammation and could therefore be low priced, easily available, and highly tolerable compounds, and long-term exposure at physiological concentrations could shape the epigenome in a desirable and cumulative manner [12]. Despite the promising results for diets rich in fruit and vegetables in terms of disease prevention, it remains unclear if additional supplementation with isolated flavonoids would have significant additional beneficial health effects in humans. Clearly, pharmacological drugs are inevitably required for cancer therapy, but it seems that flavonoids and other natural compounds could contribute to future treatment strategies.

Abbreviations

ALL: acute lymphocytic leukaemia; AML: acute myeloid leukaemia; Apc: adenomatous polyposis coli; BRCA1: breast cancer 1, early onset; CML: chronic myeloid leukaemia; CMML: chronic myelomonocytic leukaemia; COMT: catechol-O-methyltransferase; DMBA: 7,12-dimethylbenz[a]anthracene; DNMT: DNA methyltransferase; DNMTi: DNA methyltransferase inhibitor; EC: (–)-epicatechin; ECG: (–)-epicatechin-3-gallate; EGC: (–)-epigallocatechin; EGCG: (–)-epigallocatechin-3-gallate; ERα: oestrogen receptor α; ERβ: oestrogen receptor β; EZH2: histone-lysine *N*-methyltransferase gene; FDA: US Food and Drug Administration; FoxO: forkhead-box-protein O; GNAT: GCN5 *N*-acetyltransferase; HAT: histone acetyltransferase; HBP: hamster buccal pouch; HDAC: histone deacetylase; HDACi: histone deacetylase inhibitor; HDM: histone demethylase; HMT: histone methyltransferase; HR: hazard ratio; hTERT: human telomerase reverse transcriptase; IC₅₀: half maximal inhibitory concentration; LH: linker histone; MDS: myelodysplastic syndrome; MGMT: O⁶-methylguanine DNA methyltransferase; miRNA: non-coding microRNA; MYST: MOZ/YBF2/SAS2/TIP60; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; OR: odds ratio; p16^{INK4a}: cyclin-dependent kinase inhibitor 2A, multiple tumour suppressor 1; p53: tumour protein p53; pRb: retinoblastoma protein; PSA: prostate-specific antigen; RARβ: retinoic acid receptor β; RR: relative risk; RXRα: retinoid X receptor alpha; SAH: S-adenosyl-L-homocysteine; SAM: S-adenosyl methionine; SIRT: sirtuin; SRC-3: steroid receptor coactivator-3; TRAMP: transgenic adenocarcinoma of the mouse prostate; TSA: trichostatin A; UVB: ultraviolet B; Wnt: wingless-related integration site; w/v: mass/volume (mass concentration).

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CB, MB, and SV wrote the first draft of the article. CL, UML, and JF edited and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to A. Burkard for the excellent graphical assistance. This work was supported by grants from the German Childhood Cancer Foundation (DKS), Else Uebelmesser Foundation (to SV) and the Wissenschaftsfoerderung der Deutschen Brauwirtschaft e.V. project B103 (to SV, CB and JF). SV was further supported by an Innovation Grant of the Eberhard Karls University of Tuebingen. We further acknowledge support by the German Research Foundation (DFG) and the Open Access Publishing Fund of the Eberhard Karls University of Tuebingen. The sponsors had no involvement neither in the study design, collection, analysis and interpretation of data, nor in the writing of the manuscript and in the decision to submit the manuscript for publication.

Author details

¹Division of Dermatologic Oncology, Department of Dermatology and Allergology, Medical University Hospital, Tuebingen, Germany. ²Department of Internal Medicine I, Medical University Hospital, Otfried-Mueller-Str. 27, 72076 Tuebingen, Germany. ³Institute of Biological Chemistry and Nutrition, University of Hohenheim, Stuttgart, Germany.

Received: 6 March 2015 Accepted: 17 June 2015

Published online: 10 July 2015

References

- Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. *Carcinogenesis*. 2010;31(1):100–10. doi:10.1093/carcin/bgp263.
- Ong TP, Moreno FS, Ross SA. Targeting the epigenome with bioactive food components for cancer prevention. *J Nutrigenet Nutrigenomics*. 2011;4(5):275–92. doi:10.1159/000334585.
- Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell*. 2010;140(6):883–99. doi:10.1016/j.cell.2010.01.025.
- Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. *Mol Cancer Ther*. 2009;8(6):1409–20. doi:10.1158/1535-7163.MCT-08-0860.
- Gilbert ER, Liu D. Flavonoids influence epigenetic-modifying enzyme activity: structure - function relationships and the therapeutic potential for cancer. *Curr Med Chem*. 2010;17(17):1756–68.
- Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. *Exp Biol Med* (Maywood). 2004;229(10):988–95.
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell*. 2000;100(1):57–70.
- Chen RZ, Petterson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. *Nature*. 1998;395(6697):89–93. doi:10.1038/25779.
- Glozak MA, Seto E. Histone deacetylases and cancer. *Oncogene*. 2007;26(37):5420–32. doi:10.1038/sj.onc.1210610.
- Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. *J Natl Cancer Inst*. 2005;97(20):1498–506. doi:10.1093/jnci/dji311.
- Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. *Biochem Pharmacol*. 2010;80(12):1771–92. doi:10.1016/j.bcp.2010.06.036.
- Vanden BW. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. *Pharmacol Res*. 2012;65(6):565–76. doi:10.1016/j.phrs.2012.03.007.
- Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. *Cell*. 2007;128(4):635–8. doi:10.1016/j.cell.2007.02.006.
- Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet*. 2007;8(4):286–98. doi:10.1038/nrg2005.
- Kanno R, Janakiraman H, Kanno M. Epigenetic regulator polycomb group protein complexes control cell fate and cancer. *Cancer Sci*. 2008;99(6):1077–84. doi:10.1111/j.1349-7006.2008.00797.x.
- Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. Cancer genetics of epigenetic genes. *Hum Mol Genet*. 2007;16 Spec No 1:R28–49. doi:10.1093/hmg/ddm021.
- Ambros V. The functions of animal microRNAs. *Nature*. 2004;431(7006):350–5. doi:10.1038/nature02871.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004;116(2):281–97.
- Esteller M. Epigenetics in cancer. *N Engl J Med*. 2008;358(11):1148–59. doi:10.1056/NEJMra072067.
- Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. *Proc Natl Acad Sci U S A*. 2003;100(21):12253–8. doi:10.1073/pnas.2037852100.
- Simmons RA. Developmental origins of beta-cell failure in type 2 diabetes: the role of epigenetic mechanisms. *Pediatr Res*. 2007;61(5 Pt 2):64R–7. doi:10.1203/pdr.0b013e3180457623.
- Bird A. DNA methylation patterns and epigenetic memory. *Genes Dev*. 2002;16(1):6–21. doi:10.1101/gad.947102.
- Jiang YH, Bressler J, Beaudet AL. Epigenetics and human disease. *Annu Rev Genomics Hum Genet*. 2004;5:479–510. doi:10.1146/annurev.genom.5.061903.180014.
- Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, et al. De novo CpG island methylation in human cancer cells. *Cancer Res*. 2006;66(2):682–92. doi:10.1158/0008-5472.CAN-05-1980.
- Plagemann A. A matter of insulin: developmental programming of body weight regulation. *J Matern Fetal Neonatal Med*. 2008;21(3):143–8. doi:10.1080/14767050801929869.
- Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. *Sci Transl Med*. 2011;3(75):75ra25. doi:10.1126/scitranslmed.3001875.
- Park YJ, Claus R, Weichenhan D, Plass C. Genome-wide epigenetic modifications in cancer. *Prog Drug Res*. 2011;67:25–49.
- Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. *Science*. 2010;328(5979):753–6. doi:10.1126/science.1186088.
- Murgatroyd C, Patchev AV, Wu Y, Micala V, Bockmuhl Y, Fischer D, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. *Nat Neurosci*. 2009;12(12):1559–66. doi:10.1038/nn.2436.
- Lee RS, Tamashiro KL, Yang X, Purcell RH, Huo Y, Rongione M, et al. A measure of glucocorticoid load provided by DNA methylation of Fkbp5 in mice. *Psychopharmacology (Berl)*. 2011;218(1):303–12. doi:10.1007/s00213-011-2307-3.
- Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature*. 1997;389(6648):251–60. doi:10.1038/38444.
- McBryant SJ, Lu X, Hansen JC. Multifunctionality of the linker histones: an emerging role for protein-protein interactions. *Cell Res*. 2010;20(5):519–28. doi:10.1038/cr.2010.35.
- Keppeler BR, Archer TK. Chromatin-modifying enzymes as therapeutic targets—part 1. *Expert Opin Ther Targets*. 2008;12(10):1301–12. doi:10.1517/14728222.12.10.1301.
- Jenuwein T, Allis CD. Translating the histone code. *Science*. 2001;293(5532):1074–80. doi:10.1126/science.1063127.
- Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: covalent histone modifications. *Trends Mol Med*. 2007;13(9):363–72. doi:10.1016/j.molmed.2007.07.003.
- Delcuve GP, Khan DH, Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. *Clinical Epigenetics*. 2012;4(1):5. doi:10.1186/1868-7083-4-5.
- Liew CC, Chan PK. Identification of nonhistone chromatin proteins in chromatin subunits. *Proc Natl Acad Sci U S A*. 1976;73(10):3458–62.
- Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. *Nat Rev Drug Discov*. 2014;13(9):673–91. doi:10.1038/nrd4360.
- Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. *Int J Biochem Cell Biol*. 2009;41(1):87–95. doi:10.1016/j.jbiocel.2008.09.005.
- Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, et al. DNA methylation, its mediators and genome integrity. *Int J Biol Sci*. 2015;11(5):604–17. doi:10.7150/ijbs.11218.
- Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. *Mol Cancer Res*. 2007;5(10):981–9. doi:10.1158/1541-7786.MCR-07-0324.
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. *Nat Rev Drug Discov*. 2006;5(9):769–84. doi:10.1038/nrd2133.
- Marks P, Rifkin RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. *Nat Rev Cancer*. 2001;1(3):194–202. doi:10.1038/35106079.
- Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PH, Jukema JW. Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease. *Eur Heart J*. 2009;30(3):266–77. doi:10.1093/eurheartj/ehn603.
- Brandl A, Heinzl T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. *Biol Cell*. 2009;101(4):193–205. doi:10.1042/BC20080158.
- Kim HJ, Kim SH, Yun JM. Fisetin inhibits hyperglycemia-induced proinflammatory cytokine production by epigenetic mechanisms. *Evid Based Complement Alternat Med*. 2012;2012:639469. doi:10.1155/2012/639469.
- Wang J, Pae M, Meydani SN, Wu D. Green tea epigallocatechin-3-gallate modulates differentiation of naive CD4(+) T cells into specific lineage effector cells. *J Mol Med (Berl)*. 2013;91(4):485–95. doi:10.1007/s00109-012-0964-2.
- Middleton Jr E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol Rev*. 2000;52(4):673–751.
- West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. *J Clin Invest*. 2014;124(1):30–9. doi:10.1172/JCI69738.

50. Rajendran P, Ho E, Williams DE, Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. *Clinical Epigenetics*. 2011;3(1):4. doi:10.1186/1868-7083-3-4.
51. Rajendran P, Williams DE, Ho E, Dashwood RH. Metabolism as a key to histone deacetylase inhibition. *Crit Rev Biochem Mol Biol*. 2011;46(3):181–99. doi:10.3109/10409238.2011.557713.
52. Sinnberg T, Noor S, Venturelli S, Berger A, Schuler P, Garbe C, et al. The ROS-induced cytotoxicity of ascorbate is attenuated by hypoxia and HIF-1 α in the NCI60 cancer cell lines. *J Cell Mol Med*. 2014;18(3):530–41. doi:10.1111/jcmm.12207.
53. Jones PA, Baylin SB. The epigenomics of cancer. *Cell*. 2007;128(4):683–92. doi:10.1016/j.cell.2007.01.029.
54. Venturelli S, Berger A, Weiland T, Essmann F, Waibel M, Nuebling T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells. *Mol Cancer Ther*. 2013;12(10):2226–36. doi:10.1158/1535-7163.MCT-13-0137.
55. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223–32. doi:10.1016/S1470-2045(09)70003-8.
56. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. *Cancer Res*. 1970;30(11):2760–9.
57. Stressemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacitidine and decitabine. *International Journal of Cancer Journal international du cancer*. 2008;123(1):8–13. doi:10.1002/ijc.23607.
58. Warner JR, Knopf PM, Rich A. A multiple ribosomal structure in protein synthesis. *Proc Natl Acad Sci U S A*. 1963;49:122–9.
59. Cihak A. Biological effects of 5-azacytidine in eukaryotes. *Oncology*. 1974;30(5):405–22.
60. Quintas-Cardama A, Santos FP, Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. *Nat Rev Clin Oncol*. 2010;7(8):433–44. doi:10.1038/nrclinonc.2010.87.
61. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. *Cancer*. 2006;106(8):1794–803. doi:10.1002/cncr.21792.
62. Ramos MP, Wijetunga NA, McLellan AS, Suzuki M, Grealley JM. DNA demethylation by 5-aza-2'-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. *Epigenetics Chromatin*. 2015;8:11. doi:10.1186/s13072-015-0004-x.
63. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. *Mol Cancer Ther*. 2005;4(10):1515–20. doi:10.1158/1535-7163.MCT-05-0172.
64. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. *Clinical Epigenetics*. 2013;5(1):3. doi:10.1186/1868-7083-5-3.
65. Stressemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacitidine causes complex DNA methylation responses in myeloid leukemia. *Mol Cancer Ther*. 2008;7(9):2998–3005. doi:10.1158/1535-7163.MCT-08-0411.
66. Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque MP, Bocker A, et al. Epigenetic impacts of ascorbate on human metastatic melanoma cells. *Front Oncol*. 2014;4:227. doi:10.3389/fonc.2014.00227.
67. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. *Biochem J*. 2003;370(Pt 3):737–49. doi:10.1042/BJ20021321.
68. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. *Nat Rev Genet*. 2009;10(1):32–42. doi:10.1038/nrg2485.
69. Garmock-Jones KP. Panobinostat: first global approval. *Drugs*. 2015;75(6):695–704. doi:10.1007/s40265-015-0388-8.
70. Poole RM. Belinostat: first global approval. *Drugs*. 2014;74(13):1543–54. doi:10.1007/s40265-014-0275-8.
71. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. *Nat Med*. 2011;17(3):330–9. doi:10.1038/nm.2305.
72. Hollman PC, Katan MB. Dietary flavonoids: intake, health effects and bioavailability. *Food Chem Toxicol*. 1999;37(9–10):937–42.
73. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. *World Rev Nutr Diet*. 1976;24:117–91.
74. War AR, Paulraj MG, Ahmad T, Buhroo AA, Hussain B, Ignacimuthu S, et al. Mechanisms of plant defense against insect herbivores. *Plant Signal Behav*. 2012;7(10):1306–20. doi:10.4161/psb.21663.
75. Hodek P, Trefil P, Stiborova M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. *Chem Biol Interact*. 2002;139(1):1–21.
76. Malireddy S, Kotha SR, Secor JD, Gurney TO, Abbott JL, Maulik G, et al. Phytochemical antioxidants modulate mammalian cellular epigenome: implications in health and disease. *Antioxid Redox Signal*. 2012;17(2):327–39. doi:10.1089/ars.2012.4600.
77. Chung S, Yao H, Caito S, Hwang JW, Arunachalam G, Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. *Arch Biochem Biophys*. 2010;501(1):79–90. doi:10.1016/j.abb.2010.05.003.
78. Acamovic T, Brooker JD. Biochemistry of plant secondary metabolites and their effects in animals. *Proc Nutr Soc*. 2005;64(3):403–12.
79. Dinkova-Kostova AT. Phytochemicals as protectors against ultraviolet radiation: versatility of effects and mechanisms. *Planta Med*. 2008;74(13):1548–59. doi:10.1055/s-2008-1081296.
80. Dashwood RH. Frontiers in polyphenols and cancer prevention. *J Nutr*. 2007;137(1 Suppl):267S–9.
81. Brat P, George S, Bellamy A, Du Chaffaut L, Scalbert A, Mennen L, et al. Daily polyphenol intake in France from fruit and vegetables. *J Nutr*. 2006;136(9):2368–73.
82. Perez-Jimenez J, Fezeu L, Touvier M, Arnault N, Manach C, Hercberg S, et al. Dietary intake of 337 polyphenols in French adults. *Am J Clin Nutr*. 2011;93(6):1220–8. doi:10.3945/ajcn.110.007096.
83. Johannot L, Somerset SM. Age-related variations in flavonoid intake and sources in the Australian population. *Public Health Nutr*. 2006;9(8):1045–54.
84. Chun OK, Chung SJ, Song WO. Estimated dietary flavonoid intake and major food sources of U.S. adults. *J Nutr*. 2007;137(5):1244–52.
85. Graham HN. Green tea composition, consumption, and polyphenol chemistry. *Prev Med*. 1992;21(3):334–50.
86. Yang J, Mao QX, Xu HX, Ma X, Zeng CY. Tea consumption and risk of type 2 diabetes mellitus: a systematic review and meta-analysis update. *BMJ Open*. 2014;4(7), e005632. doi:10.1136/bmjopen-2014-005632.
87. Hardy TM, Tollefsbol TO. Epigenetic diet: impact on the epigenome and cancer. *Epigenomics*. 2011;3(4):503–18. doi:10.2217/epi.11.71.
88. Fujihara T, Nakagawa-Izumi A, Ozawa T, Numata O. High-molecular-weight polyphenols from oolong tea and black tea: purification, some properties, and role in increasing mitochondrial membrane potential. *Biosci Biotechnol Biochem*. 2007;71(3):711–9. doi:10.1271/bbb.60562.
89. Shen FM, Chen HW. Element composition of tea leaves and tea infusions and its impact on health. *Bull Environ Contam Toxicol*. 2008;80(3):300–4. doi:10.1007/s00128-008-9367-z.
90. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. *Crit Rev Food Sci Nutr*. 2003;43(1):89–143. doi:10.1080/1040869030826464.
91. Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. *Curr Med Chem*. 2008;15(18):1840–50.
92. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. *J Natl Cancer Inst*. 1997;89(24):1881–6.
93. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. *Curr Med Chem*. 2010;17(20):2141–51.
94. Stressemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. *Cancer Res*. 2006;66(5):2794–800. doi:10.1158/0008-5472.CAN-05-2821.
95. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. *Mol Pharmacol*. 2005;68(4):1018–30. doi:10.1124/mol.104.008367.
96. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (–)epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res*. 2003;63(22):7563–70.
97. Nandakumar V, Vaid M, Katiyar SK. (–)Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. *Carcinogenesis*. 2011;32(4):537–44. doi:10.1093/carcin/bgq285.
98. Cuevas A, Saavedra N, Salazar LA, Abdalla DS. Modulation of immune function by polyphenols: possible contribution of epigenetic factors. *Nutrients*. 2013;5(7):2314–32. doi:10.3390/nu5072314.

99. Zhu BT, Patel UK, Cai MX, Lee AJ, Conney AH. Rapid conversion of tea catechins to monomethylated products by rat liver cytosolic catechol-O-methyltransferase. *Xenobiotica*. 2001;31(12):879–90. doi:10.1080/00498250110079798.
100. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. *Drug Metab Dispos*. 2003;31(5):572–9.
101. Saavedra OM, Isakovic L, Llewellyn DB, Zhan L, Bernstein N, Claridge S, et al. SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. *Bioorg Med Chem Lett*. 2009;19(10):2747–51. doi:10.1016/j.bmcl.2009.03.113.
102. Moseley VR, Morris J, Knackstedt RW, Wargovich MJ. Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. *Anticancer Res*. 2013;33(12):5325–33.
103. Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH, Kang HB, et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. *Cancer Res*. 2009;69(2):583–92. doi:10.1158/0008-5472.CAN-08-2442.
104. Augustin K, Frank J, Augustin S, Langguth P, Ohrvik V, Witthoft CM, et al. Green tea extracts lower serum folates in rats at very high dietary concentrations only and do not affect plasma folates in a human pilot study. *J Physiol Pharmacol*. 2009;60(3):103–8.
105. Henning SM, Wang P, Said J, Magyar C, Castor B, Doan N, et al. Polyphenols in brewed green tea inhibit prostate tumor xenograft growth by localizing to the tumor and decreasing oxidative stress and angiogenesis. *J Nutr Biochem*. 2012;23(11):1537–42. doi:10.1016/j.jnutbio.2011.10.007.
106. Volate SR, Muga SJ, Issa AY, Nitcheva D, Smith T, Wargovich MJ. Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer. *Mol Carcinog*. 2009;48(10):920–33. doi:10.1002/mc.20542.
107. Mittal A, Piyathilake C, Hara Y, Katiyar SK. Exceptionally high protection of photocarcinogenesis by topical application of (-)-epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. *Neoplasia*. 2003;5(6):555–65.
108. Morey Kinney SR, Zhang W, Pascual M, Greally JM, Gillard BM, Karasik E, et al. Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate. *Cancer Prevention Research*. 2009;2(12):1065–75. doi:10.1158/1940-6207.CAPR-09-0010.
109. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SJ, Hafeez BB, Ahmad N, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. *Clin Cancer Res*. 2009;15(6):1947–53. doi:10.1158/1078-0432.CCR-08-2332.
110. Aherne SA, O'Brien NM. Dietary flavonols: chemistry, food content, and metabolism. *Nutrition*. 2002;18(1):75–81.
111. Egert S, Wolfram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner AE, Frank J, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. *J Nutr*. 2008;138(9):1615–21.
112. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidized low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. *Br J Nutr*. 2009;102(7):1065–74. doi:10.1017/S0007114509359127.
113. Egert S, Boesch-Saadatmandi C, Wolfram S, Rimbach G, Muller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. *J Nutr*. 2010;140(2):278–84. doi:10.3945/jn.109.117655.
114. Moon JH, Nakata R, Oshima S, Inakuma T, Terao J. Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. *Am J Physiol Regul Integr Comp Physiol*. 2000;279(2):R461–7.
115. Sahu BD, Kalvala AK, Koneru M, Mahesh Kumar J, Kuncha M, Rachamalla SS, et al. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-kappaB activation and antioxidant defence. *PLoS One*. 2014;9(9), e105070. doi:10.1371/journal.pone.0105070.
116. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr*. 2002;22:19–34. doi:10.1146/annurev.nutr.22.11401.144957.
117. Basli A, Soulet S, Chaher N, Merillon JM, Chibane M, Monti JP, et al. Wine polyphenols: potential agents in neuroprotection. *Oxid Med Cell Longev*. 2012;2012:805762. doi:10.1155/2012/805762.
118. Berger A, Venturelli S, Kallnischkies M, Bocker A, Busch C, Weiland T, et al. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. *J Nutr Biochem*. 2013;24(6):977–85. doi:10.1016/j.jnutbio.2012.07.001.
119. Lee WJ, Chen YR, Tseng TH. Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. *Oncol Rep*. 2011;25(2):583–91. doi:10.3892/or.2010.1097.
120. Priyadarisani RV, Vinothini G, Murugan RS, Manikandan P, Nagini S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. *Nutr Cancer*. 2011;63(2):218–26. doi:10.1080/01635581.2011.523503.
121. Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. *Mini Rev Med Chem*. 2009;9(1):31–59.
122. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. *J Nutr*. 2007;137(1 Suppl):2235–8.
123. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S. Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. *Mol Carcinog*. 2012;51(12):952–62. doi:10.1002/mc.20866.
124. Zamora-Ros R, Andres-Lacueva C, Lamuela-Raventos RM, Berenguer T, Jakszyn P, Martinez C, et al. Concentrations of resveratrol and derivatives in foods and estimation of dietary intake in a Spanish population: European Prospective Investigation into Cancer and Nutrition (EPIC)-Spain cohort. *Br J Nutr*. 2008;100(1):188–96. doi:10.1017/S0007114507882997.
125. Felgines C, Texier O, Morand C, Manach C, Scalbert A, Regeat F, et al. Bioavailability of the flavanone naringenin and its glycosides in rats. *Am J Physiol Gastrointest Liver Physiol*. 2000;279(6):G1148–54.
126. Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. *J Clin Endocrinol Metab*. 1998;83(7):2223–35. doi:10.1210/jcem.83.7.4752.
127. Rietjens IM, Sotoca AM, Vervoort J, Lousse J. Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks. *Mol Nutr Food Res*. 2013;57(1):100–13. doi:10.1002/mnfr.201200439.
128. Rimbach G, Boesch-Saadatmandi C, Frank J, Fuchs D, Wenzel U, Daniel H, et al. Dietary isoflavones in the prevention of cardiovascular disease—a molecular perspective. *Food Chem Toxicol*. 2008;46(4):1308–19. doi:10.1016/j.fct.2007.06.029.
129. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. *Clin Cancer Res*. 2005;11(19 Pt 1):7033–41. doi:10.1158/1078-0432.CCR-05-0406.
130. Zhang Y, Chen H. Genistein, an epigenome modifier during cancer prevention. *Epigenetics*. 2011;6(7):888–91.
131. Meeran SM, Patel SN, Chan TH, Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. *Cancer Prevention Research*. 2011;4(8):1243–54. doi:10.1158/1940-6207.CAPR-11-0009.
132. Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. *J Cell Biochem*. 2008;103(2):509–19. doi:10.1002/jcb.21417.
133. Li Y, Liu L, Andrews LG, Tollefsbol TO. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. *International journal of cancer Journal international du cancer*. 2009;125(2):286–96. doi:10.1002/ijc.24398.
134. Vanhees K, Coort S, Ruijters EJ, Godschalk RW, van Schooten FJ, Barjesteh van Waalwijk van Doorn-Khosrovani S. Epigenetics: prenatal exposure to genistein leaves a permanent signature on the hematopoietic lineage. *FASEB*. 2011;25(2):797–807. doi:10.1096/fj.10-172155.
135. Zhang Y, Li Q, Chen H. DNA methylation and histone modifications of Wnt genes by genistein during colon cancer development. *Carcinogenesis*. 2013;34(8):1756–63. doi:10.1093/carcin/bgt129.
136. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. *International journal of cancer Journal international du cancer*. 2008;123(3):552–60. doi:10.1002/ijc.23590.
137. Dagdemir A, Durif J, Ngollo M, Bignon YJ, Bernard-Gallon D. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. *Epigenomics*. 2013;5(1):51–63. doi:10.2217/epi.12.74.

138. Fang MZ, Jin Z, Wang Y, Liao J, Yang GY, Wang LD, et al. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. *Int J Oncol*. 2005;26(3):615–22.
139. Parker LP, Taylor DD, Kesterson J, Metzinger DS, Gercel-Taylor C. Modulation of microRNA associated with ovarian cancer cells by genistein. *Eur J Gynaecol Oncol*. 2009;30(6):616–21.
140. Allred CD, Ju YH, Allred KF, Chang J, Helferich WG. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. *Carcinogenesis*. 2001;22(10):1667–73.
141. Martinez-Montemayor MM, Otero-Franqui E, Martinez J, De La Mota-Peynado A, Cubano LA, Dharmawardhane S. Individual and combined soy isoflavones exert differential effects on metastatic cancer progression. *Clin Exp Metastasis*. 2010;27(7):465–80. doi:10.1007/s10585-010-9336-x.
142. Al-Anati L, Essid E, Reinehr R, Petzinger E. Silibinin protects OTA-mediated TNF-alpha release from perfused rat livers and isolated rat Kupffer cells. *Mol Nutr Food Res*. 2009;53(4):460–6. doi:10.1002/mnfr.200800110.
143. Jayaraj R, Deb U, Bhaskar AS, Prasad GB, Rao PV. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. *Environ Toxicol*. 2007;22(5):472–9. doi:10.1002/tox.20283.
144. Mengs U, Pohl RT, Mitchell T. Legalon(R) SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. *Curr Pharm Biotechnol*. 2012;13(10):1964–70.
145. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from *Silybum marianum* on antiproliferative end points in human prostate carcinoma cells. *Cancer Res*. 2005;65(10):4448–57. doi:10.1158/0008-5472.CAN-04-4662.
146. Kauntz H, Bousserouel S, Gosse F, Raul F. Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells. *Oncol Lett*. 2013;5(4):1273–7. doi:10.3892/ol.2013.1190.
147. Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. *World J Gastroenterol*. 2007;13(40):5299–305.
148. Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. *World J Gastroenterol*. 2009;15(16):1943–50.
149. Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. *Epigenetics*. 2012;7(10):1161–72. doi:10.4161/epi.22070.
150. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer Journal international du cancer*. 2015;136(5):E359–86. doi:10.1002/ijc.29210.
151. Kandaswami C, Perkins E, Drzewiecki G, Soloniuk DS, Middleton Jr E. Differential inhibition of proliferation of human squamous cell carcinoma, gliosarcoma and embryonic fibroblast-like lung cells in culture by plant flavonoids. *Anticancer Drugs*. 1992;3(5):525–30.
152. Middleton Jr E, Kandaswami C. Effects of flavonoids on immune and inflammatory cell functions. *Biochem Pharmacol*. 1992;43(6):1167–79.
153. Bishop KS, Ferguson LR. The interaction between epigenetics, nutrition and the development of cancer. *Nutrients*. 2015;7(2):922–47. doi:10.3390/nu7020922.
154. Ouedraogo M, Charles C, Ouedraogo M, Guissou IP, Stevigny C, Duez P. An overview of cancer chemopreventive potential and safety of proanthocyanidins. *Nutr Cancer*. 2011;63(8):1163–73. doi:10.1080/01635581.2011.607549.
155. Barnard RJ. Prevention of cancer through lifestyle changes. *Evid Based Complement Alternat Med*. 2004;1(3):233–9. doi:10.1093/ecam/neh036.
156. Chen C, Kong AN. Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. *Trends Pharmacol Sci*. 2005;26(6):318–26. doi:10.1016/j.tips.2005.04.004.
157. Nantz MP, Rowe CA, Muller C, Creasy R, Colee J, Khoo C, et al. Consumption of cranberry polyphenols enhances human gammadelta-T cell proliferation and reduces the number of symptoms associated with colds and influenza: a randomized, placebo-controlled intervention study. *Nutr J*. 2013;12:161. doi:10.1186/1475-2891-12-161.
158. Chiva-Blanch G, Uрпи-Sarda M, Llorach R, Rotches-Ribalta M, Guillen M, Casas R, et al. Differential effects of polyphenols and alcohol of red wine on the expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a randomized clinical trial. *Am J Clin Nutr*. 2012;95(2):326–34. doi:10.3945/ajcn.111.022889.
159. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, et al. Intra-individual change over time in DNA methylation with familial clustering. *JAMA*. 2008;299(24):2877–83. doi:10.1001/jama.299.24.2877.
160. Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. *Pediatr Res*. 2007;61(5 Pt 2):38R–42. doi:10.1203/pdr.0b013e31803c7b98.
161. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, et al. The antitumor activities of flavonoids. *In Vivo*. 2005;19(5):895–909.
162. Harborne JB, Williams CA. Advances in flavonoid research since 1992. *Phytochemistry*. 2000;55(6):481–504.
163. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. *Cell Signal*. 2009;21(11):1541–7. doi:10.1016/j.cellsig.2009.03.009.
164. Yao H, Xu W, Shi X, Zhang Z. Dietary flavonoids as cancer prevention agents. *J Environ Sci Health C*. 2011;29(1):1–31. doi:10.1080/10590501.2011.551317.
165. Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. *Top Curr Chem*. 2013;329:73–132. doi:10.1007/128_2012_360.
166. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *J Natl Cancer Inst*. 2008;100(11):773–83. doi:10.1093/jnci/djn148.
167. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. *Cancer Treat Rev*. 2007;33(5):407–18. doi:10.1016/j.ctrv.2007.01.005.
168. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. *International journal of cancer Journal international du cancer*. 2008;123(6):1227–39. doi:10.1002/ijc.23754.
169. Bairati I, Meyer F, Gelinias M, Fortin A, Nabid A, Brochet F, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. *J Clin Oncol*. 2005;23(24):5805–13. doi:10.1200/JCO.2005.05.514.
170. Bairati I, Meyer F, Jobin E, Gelinias M, Fortin A, Nabid A, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. *International journal of cancer Journal international du cancer*. 2006;119(9):2221–4. doi:10.1002/ijc.22042.
171. Meyer F, Bairati I, Fortin A, Gelinias M, Nabid A, Brochet F, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. *International journal of cancer Journal international du cancer*. 2008;122(7):1679–83. doi:10.1002/ijc.23200.
172. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American Society of Clinical Oncology position statement on obesity and cancer. *J Clin Oncol*. 2014;32(31):3568–74. doi:10.1200/JCO.2014.58.4680.
173. Arem H, Bobe G, Sampson J, Subar AF, Park Y, Risch H, et al. Flavonoid intake and risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study Cohort. *Br J Cancer*. 2013;108(5):1168–72. doi:10.1038/bjc.2012.584.
174. Zamora-Ros R, Sacerdote C, Ricceri F, Weiderpass E, Roswall N, Buckland G, et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Cancer*. 2014;111(9):1870–80. doi:10.1038/bjc.2014.459.
175. Shike M, Doane AS, Russo L, Cabal R, Reis-Filo J, Gerald W et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. *Journal of the National Cancer Institute*. 2014;106(9). doi:10.1093/jnci/dju189.
176. Morimoto Y, Maskarinec G, Park SY, Etienne R, Matsuno RK, Long C, et al. Dietary isoflavone intake is not statistically significantly associated with breast cancer risk in the multiethnic cohort. *Br J Nutr*. 2014;112(6):976–83. doi:10.1017/S0007114514001780.
177. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. *Breast Cancer Res Treat*. 2011;125(2):315–23. doi:10.1007/s10549-010-1270-8.
178. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. *Journal of Nutrition in Gerontology and Geriatrics*. 2012;31(3):206–38. doi:10.1080/21551197.2012.702534.
179. Knekt P, Jarvinen R, Seppanen R, Hellemaa A, Teppo L, Pukkala E, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. *Am J Epidemiol*. 1997;146(3):223–30.

180. Rossi M, Bosetti C, Negri E, Lagiou P, La Vecchia C. Flavonoids, proanthocyanidins, and cancer risk: a network of case-control studies from Italy. *Nutr Cancer*. 2010;62(7):871–7. doi:10.1080/01635581.2010.509534.
181. Garavello W, Rossi M, McLaughlin JK, Bosetti C, Negri E, Lagiou P, et al. Flavonoids and laryngeal cancer risk in Italy. *Ann Oncol*. 2007;18(6):1104–9. doi:10.1093/annonc/mdm078.
182. Rossi M, Garavello W, Talamini R, La Vecchia C, Franceschi S, Lagiou P, et al. Flavonoids and risk of squamous cell esophageal cancer. *International journal of cancer Journal international du cancer*. 2007;120(7):1560–4. doi:10.1002/ijc.22499.
183. Ekstrom AM, Serafini M, Nyren O, Wolk A, Bosetti C, Bellocchio R. Dietary quercetin intake and risk of gastric cancer: results from a population-based study in Sweden. *Ann Oncol*. 2011;22(2):438–43. doi:10.1093/annonc/mdq390.
184. Sasazuki S, Inoue M, Miura T, Iwasaki M, Tsugane S, Japan Public Health Center-based Prospective Study G. Plasma tea polyphenols and gastric cancer risk: a case-control study nested in a large population-based prospective study in Japan. *Cancer Epidemiol Biomarkers Prev*. 2008;17(2):343–51. doi:10.1158/1055-9965.EPI-07-0428.
185. Hara A, Sasazuki S, Inoue M, Iwasaki M, Shimazu T, Sawada N, et al. Isoflavone intake and risk of gastric cancer: a population-based prospective cohort study in Japan. *Am J Clin Nutr*. 2012;95(1):147–54. doi:10.3945/ajcn.111.020479.
186. Nothlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Flavonols and pancreatic cancer risk: the multiethnic cohort study. *Am J Epidemiol*. 2007;166(8):924–31. doi:10.1093/aje/kwm172.
187. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. *International journal of cancer Journal international du cancer*. 2007;121(10):2225–32. doi:10.1002/ijc.22790.
188. Cassidy A, Huang T, Rice MS, Rimm EB, Tworoger SS. Intake of dietary flavonoids and risk of epithelial ovarian cancer. *Am J Clin Nutr*. 2014;100(5):1344–51. doi:10.3945/ajcn.114.088708.
189. Miyanaga N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki M, et al. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. *Cancer Sci*. 2012;103(1):125–30. doi:10.1111/j.1349-7006.2011.02120.x.
190. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. *BMC Cancer*. 2008;8:132. doi:10.1186/1471-2407-8-132.
191. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*. 2010;70(10):1127–33. doi:10.1002/pros.21147.
192. Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S. Bioavailability of soybean isoflavones depends upon gut microflora in women. *J Nutr*. 1995;125(9):2307–15.
193. Justesen U, Knuthsen P, Leth T. Quantitative analysis of flavonols, flavones, and flavanones in fruits, vegetables and beverages by high-performance liquid chromatography with photo-diode array and mass spectrometric detection. *J Chromatogr A*. 1998;799(1–2):101–10.
194. Arabbi PR, Genovese MI, Lajolo FM. Flavonoids in vegetable foods commonly consumed in Brazil and estimated ingestion by the Brazilian population. *J Agric Food Chem*. 2004;52(5):1124–31. doi:10.1021/jf0499525.
195. Gennaro L, Leonardi C, Esposito F, Salucci M, Maiani G, Quaglia G, et al. Flavonoid and carbohydrate contents in Tropea red onions: effects of homelike peeling and storage. *J Agric Food Chem*. 2002;50(7):1904–10.
196. Mattila P, Astola J, Kumpulainen J. Determination of flavonoids in plant material by HPLC with diode-array and electro-array detections. *J Agric Food Chem*. 2000;48(12):5834–41.
197. Caldwell CR, Britz SJ, Mirecki RM. Effect of temperature, elevated carbon dioxide, and drought during seed development on the isoflavone content of dwarf soybean [*Glycine max* (L.) Merrill] grown in controlled environments. *J Agric Food Chem*. 2005;53(4):1125–9. doi:10.1021/jf0355351.
198. Charron CS, Allen FL, Johnson RD, Pantalone VR, Sams CE. Correlations of oil and protein with isoflavone concentration in soybean [*Glycine max* (L.) Merr.]. *J Agric Food Chem*. 2005;53(18):7128–35. doi:10.1021/jf050610o.
199. Chiou RY, Cheng SL. Isoflavone transformation during soybean koji preparation and subsequent miso fermentation supplemented with ethanol and NaCl. *J Agric Food Chem*. 2001;49(8):3656–60.
200. Duke SO, Rimando AM, Pace PF, Reddy KN, Smeda RJ. Isoflavone, glyphosate, and aminomethylphosphonic acid levels in seeds of glyphosate-treated, glyphosate-resistant soybean. *J Agric Food Chem*. 2003;51(1):340–4. doi:10.1021/jf025908i.
201. McCann MC, Liu K, Trujillo WA, Dobert RC. Glyphosate-tolerant soybeans remain compositionally equivalent to conventional soybeans (*Glycine max* L.) during three years of field testing. *J Agric Food Chem*. 2005;53(13):5331–5. doi:10.1021/jf0504317.
202. Wu Q, Wang M, Sciarappa WJ, Simon JE. LC/UV/ESI-MS analysis of isoflavones in Edamame and Tofu soybeans. *J Agric Food Chem*. 2004;52(10):2763–9. doi:10.1021/jf035053p.
203. Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. *Antioxid Redox Signal*. 2013;19(2):151–62. doi:10.1089/ars.2012.4901.
204. Hakkinen SH, Karenlampi SO, Mykkanen HM, Torronen AR. Influence of domestic processing and storage on flavonol contents in berries. *J Agric Food Chem*. 2000;48(7):2960–5.
205. Kosar M, Kafkas E, Paydas S, Baser KH. Phenolic composition of strawberry genotypes at different maturation stages. *J Agric Food Chem*. 2004;52(6):1586–9. doi:10.1021/jf035093t.
206. Sakakibara H, Honda Y, Nakagawa S, Ashida H, Kanazawa K. Simultaneous determination of all polyphenols in vegetables, fruits, and teas. *J Agric Food Chem*. 2003;51(3):571–81. doi:10.1021/jf020926l.
207. de Pascual-Teresa S, Santos-Buelga C, Rivas-Gonzalo JC. Quantitative analysis of flavan-3-ols in Spanish foodstuffs and beverages. *J Agric Food Chem*. 2000;48(11):5331–7.
208. Khokhar S, Venema D, Hollman PC, Dekker M, Jongen W. A RP-HPLC method for the determination of tea catechins. *Cancer Lett*. 1997;114(1–2):171–2.
209. Rechner AR, Wagner E, Van Buren L, Van De Put F, Wiseman S, Rice-Evans CA. Black tea represents a major source of dietary phenolics among regular tea drinkers. *Free Radic Res*. 2002;36(10):1127–35.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

